Summer 2026 - Translational Bioinformatics Internship at Bristol-Myers Squibb

Winter Garden, Florida, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Currently enrolled in a PhD program in bioinformatics, computational biology, biostatistics, or a related quantitative field
Proficiency in at least one scripting language (R preferred)
Familiarity with data reproducibility best practices (e.g., Git/GitHub; containers/workflows are a plus)
Experience analyzing spatial transcriptomics data and/or building prediction models using omics data types
A strong foundation of cancer biology is a plus
Must be able to work full-time for the program duration (June – August 2026)
Excellent written and verbal communication skills
All candidates must be authorized to work in the US both at the time of hire and for the duration of their employment (no immigration or visa sponsorship available)

Responsibilities

Apply predictive modeling techniques to identify candidate biomarkers that improve identification of patients with STK11 or KEAP1 genetic variations
Utilize spatial transcriptomic data to characterize molecular features associated with STK11 and KEAP1 genetic alterations in NSCLC
Flexible deliverables: Project goals may be tailored to fit the intern's interests and skills (e.g., predictive modeling can be broadened to benchmark multiple methodologies, and molecular characterization may extend to multi-modal datasets)

Skills

Bioinformatics

Spatial Transcriptomics

Predictive Modeling

Omics Datasets

Computational Modeling

Biomarkers

Transcriptomics

Multi-Modal Data Analysis

NSCLC

STK11

KEAP1

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free